107 related articles for article (PubMed ID: 11095380)
1. Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4.
Arnott ID; Shand A; Ghosh S
Am J Gastroenterol; 2000 Nov; 95(11):3326-7. PubMed ID: 11095380
[No Abstract] [Full Text] [Related]
2. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
3. Complement activation in plasma before and after infliximab treatment in Crohn disease.
Zimmermann-Nielsen E; Agnholt J; Thorlacius-Ussing O; Dahlerup JF; Baatrup G
Scand J Gastroenterol; 2003 Oct; 38(10):1050-4. PubMed ID: 14621279
[TBL] [Abstract][Full Text] [Related]
4. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
Hanauer SB
Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
[No Abstract] [Full Text] [Related]
5. Infliximab in the management of the extra-intestinal manifestations of Crohn's disease.
Lawrance IC
J Gastroenterol Hepatol; 2004 Nov; 19(11):1332-3. PubMed ID: 15482549
[No Abstract] [Full Text] [Related]
6. [Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH].
Tilg H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W;
Z Gastroenterol; 2004 Oct; 42(10):1256-63. PubMed ID: 15508068
[No Abstract] [Full Text] [Related]
7. Infliximab and the bone in Crohn's disease.
Kunisaki R; Chaki O; Taguchi T; Sugiyama T; Sugita A
Aliment Pharmacol Ther; 2005 Mar; 21(6):789-90. PubMed ID: 15771766
[No Abstract] [Full Text] [Related]
8. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
9. The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn's disease treated with Infliximab.
Vadan R; Gheorghe LS; Constantinescu A; Gheorghe C
Clin Nutr; 2011 Feb; 30(1):86-91. PubMed ID: 20719413
[TBL] [Abstract][Full Text] [Related]
10. Complications of infliximab therapy in children and adolescents affected by Crohn's disease.
Diamanti A; Papadatou B; Knafelz D; Gambarara M; Ferretti F; Castro M
Am J Gastroenterol; 2003 Dec; 98(12):2812-3. PubMed ID: 14687847
[No Abstract] [Full Text] [Related]
11. Evidence for the clinical use of infliximab in Crohn's disease.
Turner SM; Probert CS
Rom J Gastroenterol; 2003 Mar; 12(1):2-5. PubMed ID: 12673372
[No Abstract] [Full Text] [Related]
12. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
[TBL] [Abstract][Full Text] [Related]
13. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
Persoons P; Vermeire S; Demyttenaere K; Fischler B; Vandenberghe J; Van Oudenhove L; Pierik M; Hlavaty T; Van Assche G; Noman M; Rutgeerts P
Aliment Pharmacol Ther; 2005 Jul; 22(2):101-10. PubMed ID: 16011668
[TBL] [Abstract][Full Text] [Related]
14. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
16. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease.
Van Assche G; Vanbeckevoort D; Bielen D; Coremans G; Aerden I; Noman M; D'Hoore A; Penninckx F; Marchal G; Cornillie F; Rutgeerts P
Am J Gastroenterol; 2003 Feb; 98(2):332-9. PubMed ID: 12591051
[TBL] [Abstract][Full Text] [Related]
18. Infliximab treatment in a patient with Crohn's disease on haemodialysis.
Kume K; Yamasaki M; Yoshikawa I; Harada M
Colorectal Dis; 2011 Mar; 13(3):341. PubMed ID: 20082632
[No Abstract] [Full Text] [Related]
19. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
20. A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab.
Papa A; Felice C; Marzo M; Guidi L
Am J Gastroenterol; 2010 Aug; 105(8):1904. PubMed ID: 20686472
[No Abstract] [Full Text] [Related]
[Next] [New Search]